Caris Life Sciences, Inc. (BMV:CAI)
Mexico · Delayed Price · Currency is MXN | Market Cap | 146.26B -15.4% |
| Revenue (ttm) | 17.29B +85.4% |
| Net Income | 1.84B |
| EPS | 6.48 |
| Shares Out | n/a |
| PE Ratio | 79.62 |
| Forward PE | 93.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 47 |
| Open | 317.00 |
| Previous Close | 493.00 |
| Day's Range | 317.00 - 317.00 |
| 52-Week Range | 317.00 - 493.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2026 |
About Caris Life Sciences
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company’s molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecula... [Read more]
Financial Performance
In 2025, Caris Life Sciences's revenue was $812.03 million, an increase of 96.97% compared to the previous year's $412.26 million. Losses were -$537.96 million, 42.2% more than in 2024.
Financial numbers in USD Financial StatementsNews
Caris Life Sciences Earnings Call Transcript: Q2 2026
Record Q2 with 59,200 cases and 45% revenue growth, driven by commercial expansion and new product launches. Raised full-year guidance to $1.03–$1.04 billion, with continued investment in capacity and sales force. Strong demand for Caris Detect and robust financial position support ongoing innovation.
Caris Life Sciences Earnings release: Q2 2026
Caris Life Sciences released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Caris Life Sciences Slides: Q2 2026
Caris Life Sciences has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Caris Life Sciences Quarterly report: Q2 2026
Caris Life Sciences has published its Q2 2026 quarterly earnings report on August 5, 2026.
Caris Life Sciences Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Precision oncology is advancing rapidly, with strong technology leadership in whole exome and transcriptome sequencing, a growing product pipeline, and robust AI-driven data assets. Financial performance is strong, with continued reinvestment and a share repurchase reflecting confidence in future growth.
Caris Life Sciences Transcript: AGM 2026
The meeting covered board elections and auditor ratification, with all proposals approved. No shareholder questions were submitted, and final voting results will be published in a Form 8-K filing.
Caris Life Sciences Transcript: Bank of America Global Healthcare Conference 2026
Strong revenue and volume growth driven by differentiated, FDA-approved molecular profiling and AI-powered platforms. Strategic investments, expanded partnerships, and new product launches position the company for continued leadership and profitability in precision oncology.
Caris Life Sciences Earnings Call Transcript: Q1 2026
Q1 2026 saw 79% revenue growth to $216M, driven by clinical profiling and new launches. Gross margin rose to 65%, with positive adjusted EBITDA and free cash flow. Guidance for strong volume and revenue growth is reaffirmed, supported by a robust pipeline and expanded sales force.
Caris Life Sciences Earnings release: Q1 2026
Caris Life Sciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Caris Life Sciences Slides: Q1 2026
Caris Life Sciences has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Caris Life Sciences Quarterly report: Q1 2026
Caris Life Sciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Caris Life Sciences Proxy statement: Proxy filing
Caris Life Sciences filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Caris Life Sciences Proxy statement: Proxy filing
Caris Life Sciences filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Caris Life Sciences Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw record revenue and profitability, driven by strong molecular profiling growth, improved ASPs, and expanding clinical volumes. 2026 guidance projects continued double-digit growth, positive cash flow, and major investments in early detection and commercial expansion.
Caris Life Sciences Annual report: Q4 2025
Caris Life Sciences has published its Q4 2025 annual report on February 26, 2026.
Caris Life Sciences Earnings release: Q4 2025
Caris Life Sciences released its Q4 2025 earnings on February 26, 2026, summarizing the period's financial results.
Caris Life Sciences Slides: Q4 2025
Caris Life Sciences has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 26, 2026.
Caris Life Sciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong financial results and cash position support aggressive investment in technology, commercial expansion, and a robust product pipeline. Early detection and MCED programs are advancing, with new partnerships and market penetration expected to drive growth in 2026 and beyond.
Caris Life Sciences Slides: 44th Annual J.P. Morgan Healthcare Conference
Caris Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on January 12, 2026.
Caris Life Sciences Earnings Call Transcript: Q3 2025
Q3 2025 saw 113% revenue growth, record profitability, and margin expansion, driven by strong clinical profiling and higher ASPs. Guidance for FY25 was raised, with continued investment in early detection, MRD, and data platforms.
Caris Life Sciences Quarterly report: Q3 2025
Caris Life Sciences has published its Q3 2025 quarterly earnings report on November 5, 2025.
Caris Life Sciences Earnings release: Q3 2025
Caris Life Sciences released its Q3 2025 earnings on November 5, 2025, summarizing the period's financial results.
Caris Life Sciences Slides: Q3 2025
Caris Life Sciences has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 5, 2025.